Ede Frecska

Ede Frecska

Ede Frecska


Dr. Ede Frecska is the Chairman of Psychiatry at the Faculty of Medicine of the University of Debrecen. He received his medical degree in 1977 from the Semmelweis University in Hungary. He then earned qualifications as certified psychologist from the Department of Psychology at Lorand Eotvos University in Budapest. Dr. Frecska completed his residency training in Psychiatry both in Hungary (1986), and in the United States (1992). He is a qualified psychopharmacologist (1987) of international merit with 17 years of clinical and research experience in the United States, where he reached the rank of Associate Professorship. During his academic years, Dr. Frecska's studies were devoted to research on schizophrenia and affective illness. In his recent research he is engaged in studies on psychointegrator drugs, especially on the physiological effects of DMT in acute and chronic cellular stress like hypoxia. His theoretical work focuses on the interface between cognitive neuroscience and quantum brain dynamics. He is specifically interested in the mechanism of initiation ceremonies and healing rituals. He published more than 100 scientific papers and book chapters on these topics. Dr. Frecska is a member of several professional organizations (APA, ECNP, CINP), and has received grants and awards from a variety of sources (NARSAD, NIAA).

Ede Frecska is a co-author with Rick Strassman, Slawek Wojtowicz and Luis Eduardo Luna of Inner Paths to Outer Space and has chapters in Ervin Laszlo’s books (The New Science and Spirituality Reader and A New Map of Reality). A recent study lead by him, published in the Journal of Psychopharmacology, proves that ayahuasca increases creativity and another one in Frontiers in Neuroscience that DMT has neuroprotective effect in hypoxia.

The Bright Side of Dimethyltryptamine and the Dark Side of Psychedelics


Ede Frecska – Chairman of Psychiatry Clinical Center – University of Debrecen, Hungary

Attila Szabo – NORMENT, KG Jebsen Centre for Psychosis Research Institute of Clinical Medicine = University of Oslo, Norway

Botond Penke – Department of Medical Chemistry – Faculty of Medicine University of Szeged, Hungary

N,N-dimethyltryptamine (DMT) is a naturally occurring classical hallucinogen with significant affinity at 17 known receptor sites. It has also been classified as an endogenous hallucinogen. The vast majority of research on DMT has been targeting its psychotropic properties and serotonergic activity with less focus on its effects beyond the nervous system and at other receptor molecules. The recent discovery that DMT is an endogenous ligand of the sigma-1 receptor may shed light on yet undiscovered physiological and therapeutic mechanisms of DMT action and reveal some of its putative biological functions. Since the sigma-1 receptor has extensive role in mitigation of several
form of intracellular stress such as mitochondrion, endoplasmic reticulum and oxidative stress, protects against apoptotic cell death, and regulates immune processes, one may suppose similar effects after DMT administration. In the presentation, we will overview the literature on the effects of sigma-1 receptor ligands on cellular bioenergetics in
focus of ischemic-hypoxic injury. Ischemia/reperfusion is a complex phenomenon with mechanisms underlying organ transplantation, stroke, myocardial infarct, cardiac surgery, general brain hypoxia and cardiopulmonary resuscitation. We conclude that the function of DMT may extend central nervous activity and involve a more universal role in cellular protective mechanisms. We will also address the undesirable mental effects of psychedelic compounds with focus on egoinflation, spiritual narcissism (messianism), spiritual bypassing, identity diffusion, spiritual materialism, ritual addiction, and obsessions.